Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-12-19 4:22 pm Purchase | 2025-12-18 | 13D | Kodiak Sciences Inc. KOD | Baker Bros. Advisors LP | 20,067,542 32.800% | 2,713,696 (+15.64%) | Filing History |
| 2025-12-11 5:27 pm Purchase | 2025-12-09 | 13D | Kymera Therapeutics, Inc. KYMR | Baker Bros. Advisors LP | 8,676,797 10.900% | 2,010,257 (+30.15%) | Filing History |
| 2025-11-14 4:25 pm Purchase | 2025-09-30 | 13G | Immatics N.V. IMTX | Baker Bros. Advisors LP | 12,094,094 9.950% | 1,925,193 (+18.93%) | Filing History |
| 2025-11-14 4:24 pm Sale | 2025-09-30 | 13G | Cerus Corporation CERS | Baker Bros. Advisors LP | 10,028,209 5.200% | -2,875,499 (-22.28%) | Filing History |
| 2025-10-03 09:06 am Unchanged | 2025-10-02 | 13G | KALA BIO, Inc. KALA | Baker Bros. Advisors LP | 744,759 9.990% | 0 (Unchanged) | Filing History |
| 2025-10-02 8:37 pm Sale | 2025-09-30 | 13D | KALA BIO, Inc. KALA | Baker Bros. Advisors LP | 744,759 9.990% | -457,135 (-38.03%) | Filing History |
| 2025-08-18 5:52 pm Sale | 2025-08-14 | 13D | IGM Biosciences, Inc. IGMS | Baker Bros. Advisors LP | 0 0.000% | -4,145,706 (Position Closed) | Filing History |
| 2025-08-14 4:28 pm Purchase | 2025-06-30 | 13G | Edgewise Therapeutics, Inc. EWTX | Baker Bros. Advisors LP | 7,305,940 6.900% | 1,465,881 (+25.10%) | Filing History |
| 2025-08-14 4:27 pm Purchase | 2025-06-30 | 13G | Immatics N.V. IMTX | Baker Bros. Advisors LP | 10,168,901 8.400% | 2,893,071 (+39.76%) | Filing History |
| 2025-08-14 4:27 pm Sale | 2025-06-30 | 13G | Neurogene Inc. NGNE | Baker Bros. Advisors LP | 991,804 7.000% | -494,509 (-33.27%) | Filing History |
| 2025-08-14 4:26 pm Purchase | 2025-06-30 | 13G | Revolution Medicines, Inc. RVMD | Baker Bros. Advisors LP | 9,364,972 5.000% | 9,364,972 (New Position) | Filing History |
| 2025-08-14 4:26 pm Sale | 2025-06-30 | 13G | Cerus Corporation CERS | Baker Bros. Advisors LP | 12,903,708 6.800% | -6,593,495 (-33.82%) | Filing History |
| 2025-08-01 5:41 pm Purchase | 2025-08-01 | 13D | Celcuity Inc. CELC | Baker Bros. Advisors LP | 7,745,692 18.900% | 3,487,957 (+81.92%) | Filing History |
| 2025-06-30 8:26 pm Purchase | 2025-06-26 | 13D | Kymera Therapeutics, Inc. KYMR | Baker Bros. Advisors LP | 6,666,540 9.500% | 665,278 (+11.09%) | Filing History |
| 2025-06-13 5:21 pm Purchase | 2025-06-12 | 13D | Prelude Therapeutics Incorporated PRLD | Baker Bros. Advisors LP | 10,269,968 23.500% | 47,000 (+0.46%) | Filing History |
| 2025-05-15 4:33 pm Sale | 2025-03-31 | 13G | Candel Therapeutics, Inc. CADL | Baker Bros. Advisors LP | 2,455,108 4.990% | -526,875 (-17.67%) | Filing History |
| 2025-05-15 4:19 pm Purchase | 2025-03-31 | 13G | Neurogene Inc. NGNE | Baker Bros. Advisors LP | 1,486,313 9.960% | 836,628 (+128.77%) | Filing History |
| 2025-05-15 4:19 pm Sale | 2025-03-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM | Baker Bros. Advisors LP | 5,604,483 8.900% | -793,882 (-12.41%) | Filing History |
| 2025-04-07 7:04 pm Purchase | 2025-03-31 | 13G | Celcuity Inc. CELC | Baker Bros. Advisors LP | 4,257,735 11.300% | 1,579,182 (+58.96%) | Filing History |
| 2025-03-31 7:35 pm Purchase | 2025-03-27 | 13D | DBV Technologies S.A. DBVT | Baker Bros. Advisors LP | 23,489,663 17.100% | 23,489,663 (New Position) | Filing History |